Send to

Choose Destination
Ther Clin Risk Manag. 2014 Aug 16;10:651-64. doi: 10.2147/TCRM.S57509. eCollection 2014.

Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.

Author information

Department of Medicine, Division of Hematology and Oncology, George Washington University Medical Center, Washington, DC, USA.


The advent of exponential growth of novel agents tested and approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has brought about a need for understanding of the mechanism of action, side-effects, and clinical efficacy of these drugs as they relate to these patients. This review will provide a synopsis of the treatment landscape in mCRPC as varying agents such as abiraterone acetate, cabazitaxel, sipuleucel-T, radium, and selected emerging agents are presented. A distinct focus on the utilization of enzalutamide, its mechanism of action, key pivotal trials that brought about its US Food and Drug Administration approval, as well as patient-focused perspectives and clinical implications are discussed herein.


enzalutamide; metastatic castration-resistant prostate cancer; systemic therapies

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center